Sagimet Biosciences Inc. 8-K

What Happened

• Sagimet Biosciences, Inc. (SGMT) filed an 8-K reporting that Chief Medical Officer Eduardo Martins, M.D., D.Phil., retired from his role effective April 20, 2026. The filing notes Dr. Martins will continue to support the company as an external scientific advisor.
• The company also announced the appointment of Andreas Grauer, M.D., as Chief Medical Officer, effective April 20, 2026. Dr. Grauer joins Sagimet after serving as CMO at Omeros Corporation (Oct 2023–Apr 2026) and holding prior CMO and senior clinical development roles at Federation Bio, Corcept Therapeutics, Amgen, and earlier at Procter & Gamble Pharmaceuticals.

Key Details

• Retirement effective date: April 20, 2026 (Eduardo Martins, M.D., D.Phil.).
• New CMO effective date: April 20, 2026 (Andreas Grauer, M.D.).
• Dr. Grauer recent roles: CMO at Omeros (Oct 2023–Apr 2026); CMO positions at Federation Bio (Oct 2021–Jul 2023) and Corcept Therapeutics (Mar 2019–Aug 2021); VP Global Development at Amgen (Dec 2008–Dec 2018).
• Academic background: Dr. Grauer is an Associate Professor of Medicine at the University of Heidelberg Medical School, where he earned his M.D. and completed clinical training in internal medicine and endocrinology.

Why It Matters

• This is an executive leadership change affecting Sagimet’s clinical and medical development leadership. Investors should note the company has named an experienced industry CMO with prior leadership in development and regulatory-facing roles.
• Continuity is indicated by Dr. Martins’ continued involvement as an external scientific advisor, while Dr. Grauer’s background suggests operational experience to support ongoing clinical programs and regulatory interactions.